Observational studyScientific reports2025
Factors influencing the real-world effectiveness of benralizumab in uncontrolled asthma.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Response to benralizumab in patients with severe eosinophilic asthma.Revista medica del Instituto Mexicano del Seguro Social · 2026Observational
- Influence of genetic polymorphisms on omalizumab clinical response in pediatric severe asthma: a pilot study.Frontiers in pharmacology · 2026Article
- Clinical Remission in Severe Asthma: A Comparative Analysis of Patients with and Without Biologics from the Swiss Severe Asthma Registry.Biomedicines · 2025Article
- Advances and Challenges in the Development of New and Novel Treatment Strategies for Eosinophilic Esophagitis (EoE).Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a prevalent chronic respiratory condition. Most patients can manage their symptoms with standard treatments but approximately 5-10% experience severe uncontrolled asthma (SUA), characterized by persistent symptoms and frequent exacerbations despite optimized therapy. This retrospective, observational, multicentre study conducted in southern Spain aimed to evaluate the effectiveness of benralizumab in patients with SUA and identify predictive markers of response. A total of 99 patients were selected. Mean age of participants was 63 ± 15.3 years. Results showed that 79.8% of patients achieved a 50% reduction in oral corticosteroid (OCS) use, 81.8% experienced at least a 50% reduction in exacerbations, and 75.7% had a ≥ 10% improvement or maintained %forced expiratory volume in 1 s (FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.